Market Research Life Sciences Pharmaceuticals Antibiotic

ANTIBIOTIC RESISTANCE MARKETS - THERAPEUTICS.By Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides & Customization. 2020 to 2024

Lowest Prices Guaranteed Length Publisher Published Date SKU
from $6,995 411 Pages Howe Sound Research November, 2019 HSR16066876
Lowest Prices Guaranteed
Price from $6,995
Length 411 Pages
Publisher Howe Sound Research
Published Date November, 2019
SKU HSR16066876

ANTIBIOTIC RESISTANCE MARKETS - THERAPEUTICS.By Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides & Customization. 2020 to 2024

Antimicrobial Resistance is creating new kinds of infections and “superbugs” that are resistant to current antibiotic medicines. New technologies (and new drugs) are under development to capture this growing market. We have identified the 6 Key Large Opportunities in this space and developed market forecasts. We have looked at the technology picture too, giving you, plain language understanding of the different ways pathogens, and infections, can be treated, including an explanation of the key role diagnostics will play. This is a market with a lot of players, there are over 100 biotechnology companies profiled in the report. And we summarize what technologies they are using.

Our research makes you the expert in your organization. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.

All report data is available in Excel format on request."


1. Introduction and Market Definition
1.1 The Growing Threat and Opportunity of Antimicrobial Resistance
1.2 Defining the Opportunity
1.2.1 Revenue Market Size
1.3 Methods and Sources
1.3.1 Authors
1.3.2 Sources
1.4 U.S. Antibiotic Markets - Perspective
1.4.1 U.S. Outpatient Use of Antibiotics
1.4.2 U.S. Pharmaceutical Spending
2. Overview of a Dynamic Market
2.1 Market Players – Roles & Impacts
2.1.1 Drug manufacturers - Larger/pharmaceutical
2.1.2 Drug manufacturers - Generic
2.1.3 Contract Research and Manufacturing
2.1.4 In Vitro Diagnostics Industry
2.1.5 Drug Marketing Companies
2.1.6 Biotechnology Companies
2.1.7 Regulatory Bodies
2.2 Understanding Antimicrobial Resistance
2.2.1 What is Antimicrobial Resistance (AMR)
2.2.2 Bacteria and Other Microbes
2.2.3 The History of Antibiotics
2.2.4 The Role of Animal Husbandry
2.2.5 The Implications of Horizontal Transfer
2.2.6 The Threat of AMR
2.3 The Changing Road to New Antibiotics & Technologies
2.4 The Key Role of Diagnostics in AMR
3. The Market Opportunity of AMR
3.1 The Key Large Market Opportunities in AMR
3.1.1 Streptococcus Pneumoniae (DRSP)
3.1.2 Campylobacter (DRC)
3.1.3 Clostridium Difficile (CD)
3.1.4 Staphylococcus aureus (MRSA)
3.1.5 Neisseria gonorrhoeae (DRNG)
3.1.6 Salmonella (DRNTS)
3.2 Therapeutic Technology Development Opportunities
3.2.1 Using Viruses Against Bacteria
3.2.2 Hydrolytic Enzymes Join the Fight
3.2.3 Antibodies
3.2.4 Vaccines
3.2.5 Probiotic Technology
3.2.6 Peptides vs. Pathogens
3.2.7 Mining Obsolete Science
3.2.8 CRISPR Antibiotics
3.3. Antibiotic Resistance Recent Developments
3.3.1 Recent Developments – Importance and How to Use This Section
3.3.2 Importance of These Developments
3.3.3 How to Use This Section
New class of antibiotics for AMR
New AMR Drug
CRISPR Modifies Phages to target Superbugs
Genetically Modified Phage Fights 'Superbug' Infection
NIH awards $33 million grant to develop new antibiotics
Bacteria found in ancient Irish soil halts growth of superbugs
OpGen Partners With NYS DOH, Merck Subsidiary for AMR Surveillance
New breakthrough in the war against antibiotic resistance
Amicrobe, Inc., patents AMR Gel
Microneedle Patch to Combat AMR
Antimicrobial peptides find application medium
4. Key Biotechnology Companies and Their Technology
4.2 Therapeutics
4.2.1 The Medicines Company
4.2.2 Melinta Therapeutics
4.2.3 Arsanis
4.2.4 Phage Technologies S.A
4.2.5 Westway Health
4.2.6 Tetraphase Pharmaceuticals
4.2.7 BioVersys GmbH
4.2.8 Nabriva Therapeutics
4.2.9 Macrolide Pharmaceuticals
4.2.10 Nemesis Bioscience
4.2.11 C3J Therapeutics, Inc
4.2.12 EpiBiome
4.2.13 discuva
4.2.14 SmartPhage
4.2.15 AmpliPhi Biosciences
4.2.16 Pherecydes Pharma
4.2.17 Micreos
4.2.18 Procarta Biosystems
4.2.19 Lumavita
4.2.20 Madam Therapeutics
4.2.21 Priaxon
4.2.22 Biolytx Pharmaceuticals
4.2.23 AntibioTx
4.2.24 Xellia Pharmaceuticals
4.2.25 Paratek Pharmaceuticals
4.2.26 Synereca Pharmaceuticals
4.2.27 Allecra Therapeutics
4.2.28 Fixed Phage
4.2.29 Enanta Pharmaceuticals, Inc
4.2.30 Demuris
4.2.31 Prommune
4.2.32 Biosergen
4.2.33 Innovation Pharmaceuticals
4.2.34 Aviragen Therapeutics
4.2.35 Achillion Pharmaceuticals
4.2.36 ImmunNovative Developments, S.L.
4.2.37 Achaogen, Inc
4.2.38 SelectX Pharmaceuticals, Inc.
4.2.39 TaiGen Biotechnology Co., Ltd
4.2.40 Theravance Biopharma
4.2.41 Abbvie
4.2.42 KYORIN Pharmaceutical Co.,Ltd.
4.2.43 Iterum Therapeutics Limited
4.2.44 Forge Therapeutics
4.2.45 Alopexx Vaccine LLC
4.2.46 Integrated Biotherapeutics
4.2.47 Hennepin Life Sciences
4.2.48 Fedora Pharmaceuticals Inc
4.2.49 Contrafect Corporation
4.2.50 Basilea Pharmaceutica Ltd.
4.2.51 AiCuris
4.2.52 RedHill Biopharma
4.2.53 Redx Pharma Plc/ Redx Anti Infectives Ltd.
4.2.54 ABAC Therapeutics
4.2.55 Alaxia SAS
4.2.56 Antabio S.A.S
4.2.57 Auspherix Ltd
4.2.58 BioFilm Pharma
4.2.59 Centauri Therapeutics Ltd
4.2.60 Combioxin SA
4.2.61 Da Volterra
4.2.62 Debiopharm International SA
4.2.63 Deinobiotics/Deinove
4.2.64 Destiny Pharma plc
4.2.65 Eligo Bioscience
4.2.66 Helperby Therapeutics Ltd
4.2.67 Karveel Pharmaceuticals
4.2.68 MaaT Pharma
4.2.69 Motif BioSciences, Inc / Motif Bio PLC
4.2.70 Mutabilis SAS
4.2.71 Neem Biotech Ltd
4.2.72 Northern Antibiotics Oy (Ltd)
4.2.73 Nosopharm
4.2.74 NovaBiotics Ltd
4.2.75 Phico Therapeutics Ltd
4.2.76 Polyphor Ltd
4.2.77 QureTech Bio AB
4.2.78 SetLance srl
4.2.79 Ultupharma AB
4.2.80 Vaxdyn
4.2.81 Vibiosphen
4.2.82 Bioaster
4.2.83 Vivexia
4.2.85 KBP Biosciences
4.2.86 Absynth Biologics
4.2.87 Spero Therapeutics
4.2.88 Merck
4.2.89 Symphogen
4.2.90 Warp Drive Bio
4.2.91 Johnson & Johnson (Janssen)
4.2.92 Pfizer
4.2.93 Allergan
4.2.95 Novartis
4.2.97 AstraZeneca
4.2.100 Cipla
4.2.101 DSM Sinochem Pharmaceuticals
4.2.102 Wockhardt Ltd.
4.2.103 VenatoRx Pharmaceuticals
4.2.104 MicuRx
4.2.105 Entasis Therapeutics
4.2.106 Merlion Pharmaceuticals
4.2.107 Aridis Pharmaceuticals Inc
4.3 The Therapeutics Race – Summary of Companies Research Areas
5. Global Market Size
5.1 Global Market by Country
5.2 Global Market by Pathogen
5.3 Global Market by Technology
7. Market Sizes by Pathogen
7.1 DRSP Market
7.2 DRC Market
7.3 CD Market
7.4 MRSA Market
7.5 DRNG Market
7.6 DRNTS Market
7.7 Other Pathogen Market
8. Market Sizes by Technology
8.1 Antibiotics Market
8.2 Phage Market
8.3 Pep/Lys Market
8.4 Antibodies Market
8.5 Vaccine Market
8.6 Other Technology Market
9. The Future of AMR
Appendices
I. United States Medicare System: Top Selling Drugs 2011-2015
Table of Tables
Table 1 USA - Outpatient Use of Antibiotics by Class
Table 2 USA - Outpatient Use of Antibiotics Top 5
Table 3 Market Players by Type
Table 4 Known Human Pathogenic Diseases
Table 5 The Key Market Opportunities
Table 6 - Market Potential DRSP Therapeutic
Table 7 - Market Potential DRC Therapeutic
Table 8 Eight Technologies under development
Table 9 Antibodies Approved for Infectious Disease Treatment
Table 10 Therapeutic Technology Research - # of Companies
TABLE 11 GLOBAL MARKET BY COUNTRY
TABLE 12 GLOBAL MARKET BY PATHOGEN
TABLE 13 GLOBAL MARKET BY TECHNOLOGY
TABLE 14 DRSP SEGMENT BY COUNTRY
TABLE 15 DRC SEGMENT BY COUNTRY
TABLE 16 CD SEGMENT BY COUNTRY
TABLE 17 MRSA SEGMENT BY COUNTRY
TABLE 18 DRNG SEGMENT BY COUNTRY
TABLE 19 DRNTS SEGMENT BY COUNTRY
TABLE 20 OTHER PATHOGEN SEGMENT BY COUNTRY
TABLE 21 ANTIBIOTICS SEGMENT BY COUNTRY
TABLE 22 PHAGE SEGMENT BY COUNTRY
TABLE 23 PEP/LYS SEGMENT BY COUNTRY
TABLE 24 ANTIBODIES SEGMENT BY COUNTRY
TABLE 25 VACCINE SEGMENT BY COUNTRY
TABLE 26 OTHER TECHNOLOGY SEGMENT BY COUNTRY
Table 27 2011 to 2015 Top Selling Drugs
Table of Figures
Figure 1 Pharmaceutical Spending Trends
Figure 2 AMR and Antibiotic Introduction
Figure 3 The Death Toll of AMR
Figure 4 Phage T4 Anatomy and Infection Cycle
Figure 5 Key Global Markets
FIGURE 6 PATHOGEN SHARE BY YEAR
FIGURE 7 PATHOGEN SEGMENT GROWTH RATES
FIGURE 8 SEGMENT SHARE SHIFTS
Figure 9 Market Share Start Year
Figure 10 Market Share End Year
FIGURE 11 TECHNOLOGY SHARE BY YEAR
FIGURE 12 PATHOGEN SEGMENT GROWTH RATES
FIGURE 13 SEGMENT SHARE SHIFTS
Figure 14 Market Share Start Year
Figure 15 Market Share End Year
FIGURE 16 DRSP VS. TOTAL MARKET GROWTH
FIGURE 17 DRC VS. TOTAL MARKET GROWTH
FIGURE 18 CD VS. TOTAL MARKET GROWTH
FIGURE 19 MRSA VS. TOTAL MARKET GROWTH
FIGURE 20 DRNG VS. TOTAL MARKET GROWTH
FIGURE 21 DRNTS VS. TOTAL MARKET GROWTH
FIGURE 22 OTHER PATHOGEN VS. TOTAL MARKET GROWTH
FIGURE 23 ANTIBIOTICS VS. TOTAL MARKET GROWTH
FIGURE 24 PHAGE VS. TOTAL MARKET GROWTH
FIGURE 25 PEP/LYS VS. TOTAL MARKET GROWTH
FIGURE 26 ANTIBODIES VS. TOTAL MARKET GROWTH
FIGURE 27 VACCINE VS. TOTAL MARKET GROWTH
FIGURE 28 OTHER TECHNOLOGY VS. TOTAL MARKET GROWTH

$6,995
$10,495
$13,995

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings